SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Brookman May Sabine)
 

Search: WFRF:(Brookman May Sabine) > Population-based st...

Population-based study of disease trajectory after radical treatment for high-risk prostate cancer

Stattin, Pär (author)
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Fleming, Sarah (author)
Janssen Global Services, NJ, Titusville, United States
Lin, Xiwu (author)
Janssen Global Services, PA, Horsham, United States
show more...
Lefresne, Florence (author)
Janssen Research & Development, CA, Los Angeles, United States
Brookman-May, Sabine D. (author)
Janssen Research & Development, PA, Spring House, United States; Department of Urology, Ludwig-Maximilians-University, Munich, Germany
Mundle, Suneel D. (author)
Janssen Research & Development, PA, Spring House, United States
Pai, Helen (author)
Janssen Research & Development, NJ, Raritan, United States
Gifkins, Dina (author)
Janssen Research & Development, NJ, Raritan, United States
Robinson, David (author)
Department of Urology, Ryhov County Hospital, Jönköping, Sweden
Styrke, Johan (author)
Umeå universitet,Urologi och andrologi
Garmo, Hans (author)
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
show less...
 (creator_code:org_t)
John Wiley & Sons, 2024
2024
English.
In: BJU International. - : John Wiley & Sons. - 1464-4096 .- 1464-410X. ; 134:1, s. 96-102
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objectives: To investigate long-term disease trajectories among men with high-risk localized or locally advanced prostate cancer (HRLPC) treated with radical radiotherapy (RT) or radical prostatectomy (RP).Material and Methods: Men diagnosed with HRLPC in 2006–2020, who received primary RT or RP, were identified from the Prostate Cancer data Base Sweden (PCBaSe) 5.0. Follow-up ended on 30 June 2021. Treatment trajectories and risk of death from prostate cancer (PCa) or other causes were assessed by competing risk analyses using cumulative incidence for each event.Results: In total, 8317 men received RT and 4923 men underwent RP. The median (interquartile range) follow-up was 6.2 (3.6–9.5) years. After RT, the 10-year risk of PCa-related death was 0.13 (95% confidence interval [CI] 0.12–0.14) and the risk of death from all causes was 0.32 (95% CI 0.31–0.34). After RP, the 10-year risk of PCa-related death was 0.09 (95% CI 0.08–0.10) and the risk of death from all causes was 0.19 (95% CI 0.18–0.21). The 10-year risks of androgen deprivation therapy (ADT) as secondary treatment were 0.42 (95% CI 0.41–0.44) and 0.21 (95% CI 0.20–0.23) after RT and RP, respectively. Among men who received ADT as secondary treatment, the risk of PCa-related death at 10 years after initiation of ADT was 0.33 (95% CI 030–0.36) after RT and 0.27 (95% CI 0.24–0.30) after RP.Conclusion: Approximately one in 10 men with HRLPC who received primary RT or RP had died from PCa 10 years after diagnosis. Approximately one in three men who received secondary ADT, an indication of PCa progression, died from PCa 10 years after the start of ADT. Early identification and aggressive treatment of men with high risk of progression after radical treatment are warranted.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Keyword

androgen deprivation therapy
disease progression
disease trajectories
mortality
prostate cancer
prostatectomy
radiotherapy

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view